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Abstract
Background: Hemolytic and uremic syndrome (HUS) diagnosis involves association of non immune hemolytic
anemia, thrombocytopenia, and renal failure. HUS without thrombocytopenia has been observed, we call it partial
HUS. Its real frequency and outcome are unknown. The aim of this study was to determine the prevalence of
patients with normal platelets count in two HUS cohorts and to compare their outcome to patients with
thrombocytopenia.
Methods: We retrospectively identified HUS diagnosis in two different cohorts. The first cohort was from a single
center and consisted of all cases of HUS whatever the aetiology, the second was multicentric and consisted of atypical
HUS patients. These cohorts were divided into two groups depending on the presence or absence of
thrombocytopenia. Clinical and biological data were compared between thrombopenic and non thrombopenic group.
Results: We identified 13% (20/150) of patients with normal platelets count: 10 episodes (18%) of HUS in six patients
(14%) in the monocentric cohort and 14 patients (13%) with 17 episodes (12%) in the multicentric cohort of atypical
HUS. Groups differed in platelets count and LDH level. In both cohorts, renal outcome was similar to patient presenting
with thrombocytopenia.
Conclusion: HUS with normal platelets count is not infrequent. Relative to classical clinical presentation of HUS, partial
HUS has similar characteristics and identical poor renal outcome and so must be treated in the same way.
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Background
Thrombotic microangiopathy (TMA) is defined as a typical
histology characterized by intimal proliferation and/or endo-
thelial swelling with luminal fibrin deposition in arterial or
capillary beds. In the kidney, mesangiolysis, red-cell frag-
ments and double contours of capillary basement can also
be found in TMA [1]. TMA is typically associated with non-
immune mechanical haemolytic anaemia, thrombocytopenia
and organ dysfunction.
Two major syndromes can be distinguished: the haemo-
lytic uremic syndrome (HUS) and the thrombotic thrombo-
cytopenic purpura (TTP) depending on, in general speaking,
the main organ function altered, kidney in HUS and brain
in TTP. Differences in pathogenicity are observed. TTP is
associated with a defective function of the von Willebrand
factor cleaving protease (ADAMTS13) [2,3]. HUS typically
results from food poisoning with enterohemorrhagic strains
of Escherichia coli or other bacteria producing a shiga-like
toxin (STEC-HUS). Mutations in CFH, CFI, CFB, MCP, and
C3 predispose to atypical HUS (aHUS) [4-10]. Secondary
causes of HUS, due to variety of causes (such as drugs, ma-
lignancy, systemic disease. . .) occur not only in adults but
also in childhood.
Partial HUS (normal platelet count) is not well charac-
terized; we believed that this can lead to misdiagnosis of
HUS and as a result, undertreated patients or at least
delayed therapy. This delay could reduce survival.
If partial HUS is a known entity, its real frequency is
unknown. In literature, few studies address this fact
[11,12]. An occurrence between 0% and 44% is reported.
Therefore we conducted a study to describe the real
prevalence of subjects with normal platelets count in a
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single nephrology centre adult cohort of HUS, reflecting
the whole spectrum of HUS. In order to confirm preva-
lence of this entity, we also analyzed a multicentre
French cohort of adults with aHUS.
Methods
We conducted a retrospective study in the nephrology
centre at Hôpital La Conception (AP-HM, Marseille,
France). Using a computerized database, we identified all
patients with a HUS diagnosis admitted between January
2000 and June 2010. All patients’ medical records were
reviewed. Relevant clinical and biological data were col-
lected. Children were excluded.
Partial HUS was suspected by the association of
– a mechanical (with schizocytes on blood smear),
non immune (negative coombs test) haemolytic
anaemia (haemoglobin under 12 g/dl, haptoglobin
under 0,4 g/l and lactate deshydrogenase (LDH)
>250 UI/L)
– and acute renal failure (blood creatinine >120 μmol/l).
To confirm the diagnosis of partial HUS, patients were
required to have either biopsy proven TMA, and/or muta-
tion in genes coding for proteins involved in the comple-
ment alternative pathway, and/or exposition to a drug
associated with HUS like gemtacibine and/or recurrence
of partial HUS associated with response to plasmatherapy.
Complete HUS was diagnosed by the association of a
mechanical, non immune haemolytic anaemia, thrombo-
cytopenia (platelets count below 150 G/L) and acute
renal failure.
TTP was excluded by ADAMTS 13 activity above 20%.
We retrospectively compared the group of patients
with thrombocytopenia with those with normal platelets
count at diagnosis. Treatments before hospital admis-
sion, clinical and biological data on admission, treat-
ments administered, clinical outcome, renal outcome
and the number of relapses were collected. In cases of
relapses, we noted whether the diagnostic criteria were
the same.
Platelets counts were taken on the admission. However
partial HUS group was defined by the fact that during all
the disease, platelets count never decrease below 150 G/L.
Data from the thrombocytopenic group and from the
partial HUS group were analyzed further by Fisher’s exact
tests and Mann–Whitney test (two tailed) analyses.
To confirm our main result, we used a multicentre
French database to identify adult with aHUS referred be-
tween 2000 and 2008 to the laboratory of immunology
at Hôpital Européen Georges Pompidou (Paris, France),
the French reference centre for the evaluation of com-
plement disorders in human diseases. Diagnostic criteria
used were the same as those used for the first cohort.
Children were excluded. Nine patients included in the first
cohort were excluded. Clinical and biological data were
collected by the physicians who referred the patients. So,
while the Marseilles cohort included all coming HUS
patients regardless of the cause, the multicentre French
cohort was most restrictive, limited to aHUS.
This study is in compliance with the Helsinki Declar-
ation. We did not need the approval of an ethic commit-
tee to access and use the data. The access to hospital
files was given by the head of the department of neph-
rology in Marseilles and the head of the department of
immunology for the French cohort.
Results
In the Marseille database, we identified 43 patients, pre-
senting 56 episodes of HUS, over the course of ten years.
Six of the 43 patients (14%) had a total of 10 episodes
(10/56, 18%) of partial HUS.
Patients’ characteristics are summarized in Table 1.
Patients were young (median age: 45 years [25–64]) with
a majority of females (60%). Aetiologies of HUS were
those commonly described in HUS such as toxic causes,
mutations in proteins involved in alternative pathway of
the complement, and post infectious diseases.
All patients exhibited an acute renal failure (median
plasma creatinine level: 3.4 mg/dl [2.4-5.5]) and mechan-
ical, non immune haemolytic anaemia (median Hb:
7.6 g/dl [7.1-8.9], median LDH: 1012 UI/L [607–202],
and haptoglobin was not measurable). No difference was
observed for creatinine level, haemoglobin level and pro-
teinuria between the thrombocytopenic and the partial
HUS groups, while LDH levels and schizocytes count
were higher in the thrombocytopenic group.
Relapses were described in 7 patients (7/37, 19%) in the
thrombocytopenic group and in 3 patients (3/6, 50%) in the
partial HUS group. Platelets count (<150 G/L or ≥ 150
G/L) during relapses were similar to that at first episode.
Plasmatherapy were used for both groups with no dif-
ferences between number of treated patient and number
of plasmatherapy session for an episode.
Table 2 summarized patients’ characteristics for the
French cohort. We identified 107 patients presenting
145 episodes of HUS. Fourteen of the 107 patients (13%)
presented 17 episodes (17/145, 12%) of partial aHUS.
Aetiologies in this cohort represent a large panel of
mutations in proteins implicated in complement alterna-
tive pathway or a familial history of HUS. As in the
Marseille cohort, the LDH levels were significantly
higher in the thrombocytopenic aHUS group compared to
the partial aHUS group. For all other variables studied, no
difference was observed.
To assess the severity of the episode, we evaluated the
renal outcome one month after the onset of HUS. Be-
cause baseline biological data of the two cohorts seemed
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quite similar and in order to increase the power of the
study, we pooled the two cohorts. Table 3 summarizes the
outcome. 34 patients over 150 were lost-to follow up. HD
was required at the acute phase in 106/150 (71%) patients.
65/150 patients (43%) remained HD-dependant. 20/150
patients (13.6%) had persistent renal failure, and only
24/150 patients (16%) had complete recovery of their
renal function. No statistical difference could be high-
lighted between the two groups.
Discussion
We report here an occurrence of 13% (20/150) of
partial HUS patients defined by normal platelets
count at diagnosis in two independent French cohorts.
Thrombocytopenia was still absent in relapses when it
was absent during the first episode. This suggests that
the occurrence of partial HUS is frequent. No specific
cause of partial HUS was associated with lack of
thrombocytopenia.
Table 1 Data from the Marseille cohort
All patients Patients with normal platelets count Patients with thrombocytopenia p
Number of patients 43 6 37
Number of episodes 56 10 46
Number of relapsing patients 10 3 7 0.88
Sex (%male) 40% 17% 43% 0.40
Age (years) 45 [25–64] 40 [32–50] 44 [23–66] 0.78
Biopsy proven TMA 10 (23%) 3 (50%) 7 (19%) 0.38
Etiology identification 24 (56%) 3 (50%) 21 (57%)
Identified mutation 6 2 4
Anti-factor H Autoantibody 1 1
Toxic 5 1 4
Cancer associated 2 2
Graft associated 2 1
Autoimmune disease 3 3
Shiga like toxin 4 4
Post infectious disease 2 2
Potential explanation 10 (23%) 2 (33%) 8 (22.5%)
Familial form 2 2
Recurrent form 4 2 2
Associated with low C3 4 4
Idiopathic 9 (21%) 1 (17%) 8 (22.5%)
Pregnancy associated HUS 3 (11,5%) 2 (40%) 1 (5%) 0.151
Platelets (G/L)* 66 [55–108] 234 [183–265] 53 [27–88] < 0.001
Hb (g/dl) 7.6 [7.1-8.9] 8 [7.2-9.8] 7.7 [7.1-8.8] 0.38
LDH* (UI/L) 1012 [607–202] 612 [400–705] 1074 [659–2192] 0.012
Haptoglobin 0 [0–0] 0 [0–0,28] 0 [0–0] 0.064
Schizocytes %* 2.2 [1.5-3.8] 0.8 [0–2] 3 [1.5-4.4] < 0.001
Creatinine (mg/dl) 3.4 [2.4-5.5] 2.5 [1.4-5.3] 3.5 [2.5-5.6] 0.76
Proteinuria (g/24h) 2.2 [1.1 – 3.6] 1.5 [0.8 – 2.3] 2.32 [1.2 – 4] 0.15
HD at the diagnosis 12 (21%) 2 (20%) 10 (22%) 0.68
HD during the episode 34 (61%) 5 (50%) 29 (63%) 0,6
Death (%) 1 (2%) 1 (17%) 0 (0%) 0,6
Plasmatherapy
Number of episodes treated 52 (93%) 8 (80%) 44 (96%) 0.88
Number of plasmatherapy sessions 15 [12–18] 15 [6–16.5] 14 [12–20]
For Numeric value, data are express in Median value [25%-75%], for categories, data are express in number of observation (%). Test used, Mann Whitney test
(quantitative data) and Fisher's test for proportion and rate. Note, Conversion factors for units, serum creatinine in mg/dL to mol/L, ×88.4; serum urea nitrogen in
mg/dL to mmol/L.
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Normal platelets count in TMA has already been
described in previous study. Veyradier et al. [12]
reported an occurrence of 40%. However, in this study,
patients included had either HUS or TTP, with a high
proportion of secondary TMA. In others clinical reports,
Sellier-leclerc et al. reported an occurrence of 15% in a
cohort of aHUS with complement mutation [13] and
Fakhouri et al. [14] described 3 over 21 aHUS with nor-
mal platelets count in pregnancy associated HUS. In
those articles details are not mentioned and little is
known about platelets count evolution but the occur-
rence of normal platelets count seems similar to what
we noticed. Recently, De Serre et al. [11] described an
occurrence of 44% of patient with TMA and normal
Table 2 Data from the multicentric French cohort
All patients Patients with normal platelets count Patients with thrombocytopenia P
Number of patients 107 14 93
Number of episodes 145 17 128
Number of relapsing patients 18 (20%) 2 (14%) 19 (20%) 0.88
Sex (%male) 29 (27%) 5 (36%) 24 (26%) 0.39
Age (years) 32 [22 – 45] 32 [22 – 45] 33 [23 – 42] 0.78
Biopsy proven TMA 72 (67%) 13 (93%) 59 (63%)
identification of mutation 75 (70%) 10 (71%) 65 (70%) 0.95
CFH 40 6 34
CFI 17 3 14
MCP 10 1 9
C3 11 1 10
CFB 2
Anti-factor H Autoantibody 2
Potential explanation 2 (13.3%) 1 (14.3%) 11 (12%)
Familial form 1 10
Low C3 2 0 1
Idiopathic 21 (23.3%) 3 (21.4%) 19 (25%)
Pregnancy associated HUS 19 (18%) 1 (7%) 17 (18%) 0.151
Platelets (G/L)* 79 [48-117] 214 [186 - 242] 68 [46-100] < 0.001
Hb (g/dl) 7.2 [6,6 - 9] 8.6 [6.7-10] 7.2 [6.6 - 8.8] 0.16
LDH* (UI/L) 1688 [951-2930] 664 [498-1914] 1711 [999-1953] 0.017
Creatinine (mg/dl) 7.3 [4.1 - 11.3] 4.3 [2.6 - 12] 7.6 [4.6 - 11.3] 0.27
HD at the diagnosis 13 (12%) 1 (7%) 12 (13%) 0.68
HD during the episode 72 (80%) 10 (71%) 62 (81.6%) 0.6
Death Number/% 6 (6.7%) 1 (7.1%) 5 (6.6%) 0.9
For Numeric value, data are express in Median value [25%-75%], for categories, data are express in number of observation (%). Test used, Mann Whitney test
(quantitative data) and Fisher's test for proportion and rate. Note, Conversion factors for units, serum creatinine in mg/dL to mol/L, ×88.4; serum urea nitrogen in
mg/dL to mmol/L.
Table 3 Renal outcome three months after the last episode
Total Patients with normal platelets count Patients with thrombocytopenia p
Number of patient 150 20 130
Death 7 (4.7%) 2 (10%) 5 (4%) 0.55
ESRD leading to chronic haemodialysis 65 (43%) 9 (45%) 56 (43%) 0.28
CKD 20 (13.6%) 4 (20%) 16 (12%) 0.33
Recovery 24 (16%) 3 (15%) 21 (16%) 0.75
Lost 34 (22%) 2 (10%) 32 (25%) 0.21
CKD, chronic kidney injury estimated GFR in ml/min/1.73 m2 (MDRD simplified) <60 ml/min/1.73 m2. Fisher's test analysis.
ESRD, End stage renal disease.
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platelets count in a cohort of histological TMA. Never-
theless, some of the patients did not present with
haemolytic anaemia. Consequently, we assumed that
some of their description included localized TMA. In
our study, patients with partial HUS reflect the whole
TMA spectrum in a nephrology centre. Our study put in
light that biopsy is difficult to manage in the course of
HUS. Consequently, histological diagnosis of HUS is
often difficult to confirm. One limitation of our study is
in some patients with partial HUS, a kidney biopsy lacks
to absolutely confirm the diagnosis of renal TMA. We
have only indirect clinical evidence by the presence of a
mutation in the genes coding for complement alternative
pathway and/or response to plasmatherapy, in favour of
the diagnosis of HUS.
Nevertheless, this study underlines a similar renal out-
come of HUS whatever the platelets count, even if haemoly-
sis is more severe in cases with thrombocytopenia. This
similar outcome is not explained by the fact that in normal
platelets count, patient did not experiment plasmatherapy.
Renal outcome impacts on the prognosis of HUS. A poor
outcome, leading to irreversible kidney injury or death, is
described in both groups. This confirms data from De Serres
et al. [11]. They described a poor renal outcome and a worse
survival in the group with normal platelets count compared
to the thrombocytopenic group. The authors argued that a
worst outcome may be related to delay in patient care. Our
patients with partial HUS had a median delay to diagnosis
of 11 days. This can explain the similar outcome in our two
groups. We believed that normal platelets count can delay
HUS diagnosis and that kidney biopsy is the key to confirm
the diagnosis. Thus we recommend performing renal biopsy
if it is possible as soon as possible in patient with haemolytic
anaemia and kidney impairment. It is also critical to investi-
gate the alternative pathway of complement by measure of
the complement protein and research of mutations in the
genes controlling this pathway. The diagnosis could elicit
the initiation of the treatment of HUS. Our data provide a
strong argument that patient with partial HUS would benefit
from the same therapy as for thrombocytopenic HUS.
This study questions whether platelets count is the
best criterion to evaluate response to treatment in HUS.
Indeed, TMA can persist even when thrombocytopenia
has resolved. Improvement of kidney function or other
organs involvement like brain or heart could be retained
as real response criterion in HUS[15]. The LDH levels
cannot be used alone as it has already been reported as a
less important biomarker [16,17]. More accurate biomar-
kers of HUS activity are yet to be found to optimise
patients’ care.
Conclusion
Thrombocytopenia is not necessary to evoke HUS diag-
nosis. The association of mechanical haemolytic anaemia
and renal injury in the absence of thrombocytopenia
should lead to perform a renal biopsy in order to diag-
nose partial HUS. Normal platelets count is not asso-
ciated with favourable renal prognosis in HUS.
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